Elaia

☀️ Our annual Founder Summit is back! Over two and a half days in the South of France last month, we brought together nearly 100 entrepreneurs from the #ElaiaFamily to focus on the opportunities and challenges of generation GenAI and shaping full stack founder support that delivers real impact. A big thank you to our speakers who lent their time, wisdom and honest insights throughout our breakout sessions and fireside chats: Thomas Mesnard, Sophie Marchessou, Arnaud Guérin, Jimmy ANIDJAR, Florian Bressand, David Durrleman, Deepak Prakash, Anne-Claire BASCHET, Grégoire Mialon and Franck Tetzlaff. Want to catch a glimpse of this year’s edition? Scroll through for a few photos from this year’s unforgettable Summit and stay tuned for our video coming soon ➡️

⚙️ Ever wondered how Elaia supported the beginnings of tech transfer in the French ecosystem? Elaia Managing Partner, Pauline Roux, joins Solenne Niedercorn-Desouches on the Finscale podcast to chat all things startups, European capital and science-intensive tech. Want to listen to the full episode? Catch it on YouTube 👉 https://lnkd.in/emwvmGYT

SeqOne acquires Life & Soft to bolster SeqOne's multi-omics capabilities! This new collaboration significantly expands SeqOne's capabilities in: • Building advanced infectious disease, microbiome & metagenomics NGS pipelines • Enhanced on-premise lab automation tools • Expert-led custom bioinformatics services Read the full release here ➡️ https://lnkd.in/eXxHRcxw

SandboxAQ has announced the close of its Series E round, raising over $450 million in new funding and welcoming a powerhouse group of strategic investors, including Ray Dalio, Horizon Kinetics LLC, BNP Paribas, Google, and NVIDIA. Since its 2022 spin-out from Alphabet, SandboxAQ has raised a total of $950 million to advance the scale and performance of their science-driven Large Quantitative Models (LQMs), tackling complex challenges across sectors such as life sciences, advanced materials, financial services and more. Check out the news here 👉 https://lnkd.in/dZ2ShXxd Congrats to the entire SandboxAQ team!

💉 Get to know HEPHAISTOS-Pharma’s CEO, Frederic CAROFF! HEPHAISTOS-Pharma targets the innate immune system to address the key issues of tumor resistance today, especially patients who are facing hard-to-treat and solid tumors such as sarcoma or rectal cancer. Without any current therapeutic solutions on the market today, Hephaistos offers a solution that can be used both in mono- and combined therapies. Learn more here 👉 https://lnkd.in/e73dcCsk

🎉Meet Elaia's newest Deep Tech Seed Analyst: Elfwa Ljungdahl! Born in Stockholm and a graduate of Chalmers University of Technology, Elfwa brings a mix of international experience to the Elaia team, having spent time in cities including Paris, Berlin, and Brussels. Most recently, she was an analyst at Neudi & C:o AB, a Stockholm based family office, focusing on portfolio support, investment opportunities, and deal analysis. 🌎 Elfwa is particularly committed to transformative technologies - especially in the fields of life sciences, climate tech, and AI so don’t hesitate to reach out to her if you’re building in these spaces!

📓 Ever wondered how Elaia Managing Partner, Anne-Sophie CARRESE, got her start in deep tech? In conversation with Gilles Fontaine and Guillaume Payan on the latest episode of the Challenges #DeepTechs podcast, Anne-Sophie shares how her roots in aeronautical engineering laid the groundwork for building out the deep tech practice at Elaia nearly ten years ago. Tune in here 👉 https://lnkd.in/eWeaaGg6

🇺🇸 Will you be in the Bay Area for NVIDIA #GTC2025 next week? Don't miss the opportunity to connect with the Elaia team on the ground, including Alexis Frentz, Investment Director, and Clément Vanden Driessche, Partner, at one of the biggest events in AI. Want to see Elaia onstage? Catch Clément in the VC reverse pitch session on March 19th from 2-3pm!

🩻 GLEAMER acquires PIXYL and Caerus Medical! Why does this matter? Because now, Gleamer is the only provider with proprietary AI-driven solutions across all major imaging types—X-ray, Mammography, CT, and MRI. This isn’t just about growing bigger—it’s about giving radiologists the absolute best tools to work faster, spot issues more accurately, and make patient care smoother and swifter with next-generation imaging solutions. Congratulations Christian Allouche, Noé Poyet and the Gleamer team!

🔦 Elaia is looking for our next three interns! We are offering the opportunity to join as: 👾 A VC Analyst intern for our Digital Venture fund, which invests from Seed to Series B in unicorns such as Mirakl and Criteo and rising stars like Vibe.co and Mitiga Solutions 🧬 A VC Analyst intern for our Deep Tech Seed fund, which invests from pre-seed to seed tech-intensive startups like Sonio, AQEMIA and Alice & Bob ⚙️ A Compliance Intern to work closely with our head of Compliance, working on audit, risk management and AML/KYC processes At Elaia, we ❤️ technology & innovation and we pursue performance with passion & strong values: 🤝 Team spirit is core to what we do 🙌 We encourage each other to strive for personal & collective excellence 👥 We practice transparency towards both our team and our entrepreneurs We care about creating an environment where everyone is inspired to thrive & develop together. Some of the values that we encourage in the team early on are proactivity, autonomy and responsibility. If these values sound like you and you thrive in a technical, analytical, and fast-paced culture, we’d be glad to have you onboard! Check out the comments for the links to apply!